Bio
Ms Hodits is a Venture Partner in the Life Sciences group. She joined Atlas Venture in 2004 and focuses on investments across Europe. She began her career in venture capital in 2000 with Apax Partners in Munich, where she was responsible for life science investments and was closely involved with Apax’ investments in Genmab, Silence Therapeutics, Astex and Wilex. Prior to Apax Partners, she was an industry specialist for pharmaceutical and biotech companies at McKinsey & Company focusing on building new businesses, spin-offs and mergers in the sector. Ms Hodits currently serves on the Boards of Atlas portfolio companies Fibrex, f-star, Jenavalve and Bicycle Therapeutics where she was founding investor. In addition, she sits on the Boards of Atlas portfolio companies Egalet, Lumavita, Nitec, NovaMed and ProtAffin. She is an external director at GlaxoSmithKline (GSK) Respiratory CEDD. Ms Hodits was also on the Board of U3 Pharma which was acquired by Daiichi Sankyo Co Ltd in 2008. Ms Hodits holds a PhD in Biochemistry, an MSc from the Technical University in Vienna, Austria and she completed her post-doctoral research at the MRC in Cambridge, UK. In addition Ms Hodits has been the recipient of a number of scientific awards and research grants, and has published in several journals, including Nature Biotech and JBC.
Career
|
Wellington Partners Venture Capital GmbH |
||
|
Atlas VentureEarly-stage venture capital firm that creates and invests in biotechnology startup companies in the US. |
||
|
Atlas Venture LLPEarly-stage venture capital firm that creates and invests in biotechnology startup companies in the US. |